



Advancing Research. Improving Lives.™

ALCHEMIST

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

Anjali Rohatgi, MD PhD

NRG Oncology Semi-Annual
Meeting
July 2022



@NRGOnc



NRG Oncology





Disclosures: None

Accruing ALCHEMIST Trials


A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A081801: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

E4512: Crizotinib in Treating Patients with Stage IB-IIIA NSCLC that has been Removed by Surgery and ALK Fusion

ALCHEMIST Accrual (As of 7/1/2022)		
Total Sites open for A151216	1281	
Study	# Registered	# Target
A151216 (Screening)	6589	8300
A081105 (EGFR) closed 1/20/21	390	450
E4512 (ALK)	136	168
A081801 (Chemo-IO)	254	1210
EA5142 (ANVIL), closed 10/1/19	935	903

ALCHEMIST Accrual by Quarter



Screening


ALK

Chemo-IO


—●—	A151216, Total: 6510/8300
—x—	A081105, Total: 390/450 (Closed to accrual 1/20/2021)
—+—	E4512, Total: 134/168
—◇—	EA5142, Total: 935/903 (Closed to accrual 10/1/2019)
—x—	A081801, Total: 227/1210

as of 4/20/2022

Updated Study Design



Accrual





Acknowledgements



Grant/Sponsor Acknowledgements

The ALCHEMIST studies are being coordinated by the Alliance for Clinical Trials in Oncology and the ECOG-ACRIN Cancer Research Group, members of the NCI-sponsored National Clinical Trials Network (NCTN), as part of the institute's national strategy for precision medicine.

NCT02194738 (Screening A151216), NCT02193282 (EGFR A081105), NCT02201992 (ALK E4512), NCT02595944 (ANVIL, EA5142), NCT04267848 (Chemo-IO A081801)



@NRGOnc



NRG Oncology

